182 related articles for article (PubMed ID: 21464773)
1. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream.
Garcia MS; Ono Y; Martinez SR; Chen SL; Goodarzi H; Phan T; Wehrli LN; Miyamura Y; Fung MA; Maverakis E
Melanoma Res; 2011 Jun; 21(3):235-43. PubMed ID: 21464773
[TBL] [Abstract][Full Text] [Related]
2. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: results of a case series.
Shi VY; Tran K; Patel F; Leventhal J; Konia T; Fung MA; Wilken R; Garcia MS; Fitzmaurice SD; Joo J; Monjazeb AM; Burrall BA; King B; Martinez S; Christensen SD; Maverakis E
J Am Acad Dermatol; 2015 Oct; 73(4):645-54. PubMed ID: 26259990
[TBL] [Abstract][Full Text] [Related]
3. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma.
Green DS; Bodman-Smith MD; Dalgleish AG; Fischer MD
Br J Dermatol; 2007 Feb; 156(2):337-45. PubMed ID: 17223875
[TBL] [Abstract][Full Text] [Related]
4. T Cells Dominate the Local Immune Response Induced by Intralesional IL-2 in Combination with Imiquimod and Retinoid for In-Transit Metastatic Melanoma.
Ogawa H; Luxardi G; Kirane A; Kulkarni R; Monjazeb AM; Cheng MY; Ma C; Maverakis E
J Invest Dermatol; 2018 Jun; 138(6):1442-1445. PubMed ID: 29291382
[No Abstract] [Full Text] [Related]
5. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
Bong AB; Bonnekoh B; Franke I; Schön M; Ulrich J; Gollnick H
Dermatology; 2002; 205(2):135-8. PubMed ID: 12218228
[TBL] [Abstract][Full Text] [Related]
6. [Imiquimod, pegylated interferon-alpha-2b and interleukin-2 in the treatment of cutaneous melanoma metastases].
Loquai C; Nashan D; Metze D; Beiteke U; Rüping KW; Luger TA; Grabbe S
Hautarzt; 2004 Feb; 55(2):176-81. PubMed ID: 14968329
[TBL] [Abstract][Full Text] [Related]
7. Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma.
Green DS; Dalgleish AG; Belonwu N; Fischer MD; Bodman-Smith MD
Br J Dermatol; 2008 Sep; 159(3):606-14. PubMed ID: 18616776
[TBL] [Abstract][Full Text] [Related]
8. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2].
Dehesa LA; Vilar-Alejo J; Valerón-Almazán P; Carretero G
Actas Dermosifiliogr; 2009 Sep; 100(7):571-85. PubMed ID: 19715642
[TBL] [Abstract][Full Text] [Related]
9. Treatment of in-transit and metastatic melanoma in two patients treated with ipilimumab and topical imiquimod.
Joseph RW; Cappel M; Tzou K; Bagaria S; Gilstrap C; Swaika A; Jambusaria-Pahlajani A
Melanoma Res; 2016 Aug; 26(4):409-12. PubMed ID: 27138458
[TBL] [Abstract][Full Text] [Related]
10. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin.
Miller AK; Dusing R; Meggison A; Aires D
J Drugs Dermatol; 2011 Mar; 10(3):302-5. PubMed ID: 21369648
[TBL] [Abstract][Full Text] [Related]
11. Treatment of locally metastatic melanoma: a novel approach.
Shistik G; Prakash AV; Fenske NA; Glass LF
J Drugs Dermatol; 2007 Aug; 6(8):830-2. PubMed ID: 17763615
[TBL] [Abstract][Full Text] [Related]
12. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil.
Florin V; Desmedt E; Vercambre-Darras S; Mortier L
Invest New Drugs; 2012 Aug; 30(4):1641-5. PubMed ID: 21748297
[TBL] [Abstract][Full Text] [Related]
13. Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream.
Ray CM; Kluk M; Grin CM; Grant-Kels JM
Int J Dermatol; 2005 May; 44(5):428-34. PubMed ID: 15869545
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases.
Radny P; Caroli UM; Bauer J; Paul T; Schlegel C; Eigentler TK; Weide B; Schwarz M; Garbe C
Br J Cancer; 2003 Nov; 89(9):1620-6. PubMed ID: 14583759
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of persistent melanoma in situ with 5% imiquimod cream.
Muñoz CM; Sánchez JL; Martín-García RF
Dermatol Surg; 2004 Dec; 30(12 Pt 2):1543-5. PubMed ID: 15606836
[TBL] [Abstract][Full Text] [Related]
16. [Complete remission of cutaneous satellite and in-transit metastases. After intralesional therapy with interleukin-2 in 2 patients with malignant melanoma].
Pföhler C; Steinhäuser S; Wagner A; Ugurel S; Tilgen W
Hautarzt; 2004 Feb; 55(2):171-5. PubMed ID: 14968328
[TBL] [Abstract][Full Text] [Related]
17. Detailed protocol for administration of intralesional IL-2 for the treatment of Stage IIIc and IV M1a metastatic melanoma based on current NCCN guidelines.
Patel F; Wilken R; Burrall B; Martinez S; Wells V; King B; Maverakis E
Dermatol Online J; 2014 Nov; 20(11):. PubMed ID: 25419744
[TBL] [Abstract][Full Text] [Related]
18. Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy.
Heber G; Helbig D; Pönitzsch I; Wetzig T; Harth W; Simon JC
J Dtsch Dermatol Ges; 2009 Jun; 7(6):534-6. PubMed ID: 19250248
[TBL] [Abstract][Full Text] [Related]
19. Treatment of in-transit melanoma with intralesional bacillus Calmette-Guérin (BCG) and topical imiquimod 5% cream: a report of 3 cases.
Kibbi N; Ariyan S; Faries M; Choi JN
J Immunother; 2015; 38(9):371-5. PubMed ID: 26448581
[TBL] [Abstract][Full Text] [Related]
20. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients.
Ridolfi L; Ridolfi R; Ascari-Raccagni A; Fabbri M; Casadei S; Gatti A; Trevisan G; Righini MG
J Eur Acad Dermatol Venereol; 2001 May; 15(3):218-23. PubMed ID: 11683284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]